As­traZeneca hauls kid­ney dis­ease drug in­to the clin­ic af­ter hand­ing Io­n­is $30M in cash, $300M in mile­stones

More than a year af­ter As­traZeneca $AZN grabbed two of Io­n­is’ $IONS an­ti­sense drug can­di­dates in back-to-back deals, the phar­ma gi­ant has come back with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA